UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of Report: September 29, 2005
(Date of earliest event reported)
ABIOMED, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
04-2743260 |
|
(State or
Other Jurisdiction of |
|
(IRS
Employer Identification |
001-09585
(Commission File Number)
Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978) 777-5410
(Registrant’s Telephone Number, including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Election of Director.
On September 29, 2005, ABIOMED, Inc. elected Louis E. Lataif, Dean of the Boston University School of Management, as a member of its Board of Directors. Mr. Lataif will serve as a Class II director until our next annual meeting of stockholders and thereafter until his successor is duly elected and qualified. Although we expect that Mr. Lataif will be appointed to serve on at least one committee of the board of directors, the committees on which he will serve have not been determined at the time of this disclosure. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
ABIOMED, Inc. |
||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ Charles B. Haaser |
|
|
|
|
Charles B. Haaser |
|
|
|
|
Controller |
|
|
|
|
Principal Accounting Officer |
|
|
|
|
Principal Financial Officer |
|
|
|
|
||
|
|
|
||
|
Date: October 4, 2005 |
|
||
3